C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and Function: Further Evidence of a Mechanistic Link between C-Reactive Protein and Cardiovascular Disease

Circulation

Volumn 109, Issue 17, 2004, Pages 2058-2067

  Verma, Subodh ^a,c   Kuliszewski, Michael A ^b   Li, Shu Hong ^a   Szmitko, Paul E ^a   Zucco, Liana ^b   Wang, Chao Hung ^a   Badiwala, Mitesh V ^a   Mickle, Donald A G ^a   Weisel, Richard D ^a   Fedak, Paul W M ^a   Stewart, Duncan J ^b   Kutryk, Michael J B ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Apoptosis; C reactive protein; Cells; Nitric oxide synthase

Indexed keywords

ANGIOPOIETIN RECEPTOR; C REACTIVE PROTEIN; CADHERIN; CELL MARKER; EC LECTIN; LECTIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RECOMBINANT PROTEIN; ROSIGLITAZONE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTHELIUM PRECURSOR CELL; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; MALE; NORMAL HUMAN; PRECURSOR; PRIORITY JOURNAL; PROTEIN FUNCTION;

APOPTOSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2442422177     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000127577.63323.24     Document Type: Article

References (43)

1. Ejiri M, Fujita M, Sakai O, et al. Development of collateral circulation after acute myocardial infarction: its role in preserving left ventricular function. J Cardiol. 1990;20:S31-S37.
2. Hirai T, Fujita M, Nakajima H, et al. Importance of collateral circulation for prevention of left ventricular aneurysm formation in acute myocardial infarction. Circulation. 1989;79:791-796.
3. Banerjee AK, Madan Mohan SK, Ching GW, et al. Functional significance of coronary collateral vessels in patients with previous "Q" wave infarction: relation to aneurysm, left ventricular end diastolic pressure and ejection fraction. Int J Cardiol. 1993;38:263-271.
4. Kodama K, Kusuoka H, Sakai A, et al. Collateral channels that develop after an acute myocardial infarction prevent subsequent left ventricular dilation. J Am Coll Cardiol. 1996;27:1133-1139.
5. Mills JD, Fischer D, Villanueva FS. Coronary collateral development during chronic ischemia: serial assessment using harmonic myocardial contrast echocardiography. J Am Coll Cardiol. 2000;36:618-624.
6. Szmitko PE, Fedak PWM, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003;107:3093-3100.
7. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
8. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85: 221-228.
9. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438.
10. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000;87:728-730.
11. Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol. 2002; 30:967-972.
12. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: a pilot study and a randomized control trial. Lancet. 2002;360:427-435.
13. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
14. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:e1-e7.
15. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348:593-600.
16. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
17. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481-2485.
18. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
19. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
20. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part 1. Circulation. 2003;108:1917-1923.
21. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
22. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
23. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790.
24. Verma S, Wang CH, Weisel RD, et al. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol. 2003;35:417-419.
25. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370-372.
26. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
27. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Circulation. 2003;107:398-404.
28. Verma S, Badiwala MV, Weisel RD, et al. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg. 2003;126:1886-1891.
29. Wang CH, Weisel RD, Liu PP, et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation. 2003;107:1350-1354.
30. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781-2786.
31. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999;99: 2239-2242.
32. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
33. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
34. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101: 2567-2578.
35. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Med. 2003;9:1370-1376.
36. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
37. Strehlow K, Wemer N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation. 2003;107:3059-3065.
38. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator-activated receptor λ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-57.
39. Ikeda U, Shimpo M, Murakama Y, et al. Peroxisome proliferator-activated receptor-λ ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 2000;35:1232-1236.
40. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394-402.
41. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19: 2094-2104.
42. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126-3132.
43. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.